8-18064412-T-C

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_177924.5(ASAH1):​c.457+45A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.617 in 1,336,928 control chromosomes in the GnomAD database, including 259,612 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.63 ( 30581 hom., cov: 32)
Exomes 𝑓: 0.61 ( 229031 hom. )

Consequence

ASAH1
NM_177924.5 intron

Scores

8

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -1.14

Publications

10 publications found
Variant links:
Genes affected
ASAH1 (HGNC:735): (N-acylsphingosine amidohydrolase 1) This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015]
ASAH1 Gene-Disease associations (from GenCC):
  • ASAH1-related sphingolipidosis
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • Farber lipogranulomatosis
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
  • spinal muscular atrophy-progressive myoclonic epilepsy syndrome
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp, G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=3.4235284E-6).
BP6
Variant 8-18064412-T-C is Benign according to our data. Variant chr8-18064412-T-C is described in ClinVar as Benign. ClinVar VariationId is 259281.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.672 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ASAH1NM_177924.5 linkc.457+45A>G intron_variant Intron 6 of 13 ENST00000637790.2 NP_808592.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ASAH1ENST00000637790.2 linkc.457+45A>G intron_variant Intron 6 of 13 1 NM_177924.5 ENSP00000490272.1

Frequencies

GnomAD3 genomes
AF:
0.631
AC:
95896
AN:
151900
Hom.:
30564
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.679
Gnomad AMI
AF:
0.597
Gnomad AMR
AF:
0.550
Gnomad ASJ
AF:
0.501
Gnomad EAS
AF:
0.504
Gnomad SAS
AF:
0.470
Gnomad FIN
AF:
0.663
Gnomad MID
AF:
0.652
Gnomad NFE
AF:
0.644
Gnomad OTH
AF:
0.631
GnomAD2 exomes
AF:
0.577
AC:
125685
AN:
217760
AF XY:
0.576
show subpopulations
Gnomad AFR exome
AF:
0.679
Gnomad AMR exome
AF:
0.399
Gnomad ASJ exome
AF:
0.514
Gnomad EAS exome
AF:
0.511
Gnomad FIN exome
AF:
0.683
Gnomad NFE exome
AF:
0.652
Gnomad OTH exome
AF:
0.594
GnomAD4 exome
AF:
0.615
AC:
728388
AN:
1184910
Hom.:
229031
Cov.:
16
AF XY:
0.609
AC XY:
365669
AN XY:
600402
show subpopulations
African (AFR)
AF:
0.680
AC:
18404
AN:
27058
American (AMR)
AF:
0.418
AC:
17707
AN:
42410
Ashkenazi Jewish (ASJ)
AF:
0.514
AC:
12383
AN:
24114
East Asian (EAS)
AF:
0.500
AC:
18535
AN:
37042
South Asian (SAS)
AF:
0.454
AC:
35509
AN:
78240
European-Finnish (FIN)
AF:
0.680
AC:
35152
AN:
51674
Middle Eastern (MID)
AF:
0.603
AC:
3170
AN:
5256
European-Non Finnish (NFE)
AF:
0.641
AC:
556768
AN:
868130
Other (OTH)
AF:
0.603
AC:
30760
AN:
50986
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
14408
28816
43223
57631
72039
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
13072
26144
39216
52288
65360
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.631
AC:
95960
AN:
152018
Hom.:
30581
Cov.:
32
AF XY:
0.626
AC XY:
46471
AN XY:
74292
show subpopulations
African (AFR)
AF:
0.679
AC:
28135
AN:
41464
American (AMR)
AF:
0.550
AC:
8405
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.501
AC:
1734
AN:
3462
East Asian (EAS)
AF:
0.504
AC:
2608
AN:
5172
South Asian (SAS)
AF:
0.469
AC:
2257
AN:
4812
European-Finnish (FIN)
AF:
0.663
AC:
6994
AN:
10554
Middle Eastern (MID)
AF:
0.663
AC:
195
AN:
294
European-Non Finnish (NFE)
AF:
0.644
AC:
43753
AN:
67958
Other (OTH)
AF:
0.633
AC:
1337
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1825
3650
5475
7300
9125
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
782
1564
2346
3128
3910
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.631
Hom.:
84063
Bravo
AF:
0.622
TwinsUK
AF:
0.653
AC:
2421
ALSPAC
AF:
0.641
AC:
2469
ESP6500AA
AF:
0.672
AC:
2955
ESP6500EA
AF:
0.642
AC:
5513
ExAC
AF:
0.572
AC:
68618
Asia WGS
AF:
0.532
AC:
1852
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
Jun 19, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Spinal muscular atrophy-progressive myoclonic epilepsy syndrome Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Farber lipogranulomatosis Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.085
BayesDel_noAF
Benign
-0.86
CADD
Benign
0.021
DANN
Benign
0.52
DEOGEN2
Benign
0.0060
T
FATHMM_MKL
Benign
0.013
N
LIST_S2
Benign
0.29
T
MetaRNN
Benign
0.0000034
T
PhyloP100
-1.1
GERP RS
-0.49
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2073574; hg19: chr8-17921921; COSMIC: COSV50502582; COSMIC: COSV50502582; API